Cato Mork
Overview
Explore the profile of Cato Mork including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
638
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skystad Kvernebo M, Grayson C, Stylianou I, Woloshen V, Radomski C, Mork C, et al.
Acta Derm Venereol
. 2025 Jan;
105:adv42022.
PMID: 39850993
Gain-of-function variants in the voltage-gated sodium channel Nav1.7, encoded by the SCN9A gene, have previously been identified in patients with erythromelalgia, a clinical diagnosis defined by intermittent attacks of painful,...
2.
Mork E, Mjones P, Foss O, Mork C, Bachmann I, Kroon S, et al.
Acta Derm Venereol
. 2024 May;
104:adv18308.
PMID: 38751175
Photodynamic therapy is an approved treatment for primary, superficial, and small nodular basal cell carcinomas with a thickness of < 2 mm located on low-risk sites. Histologically verified basal cell...
3.
Christensen E, Mork E, Foss O, Mork C, Kroon S, Dotterud L, et al.
PLoS One
. 2024 Mar;
19(3):e0299718.
PMID: 38457386
Background: Topical photodynamic therapy (PDT) is an approved and widely used treatment for low-risk basal cell carcinoma (BCC), comprising two sessions with an interval of 1 week. Simplification of the...
4.
Brun M, Gehin J, Bjorlykke K, Warren D, Klaasen R, Sexton J, et al.
Lancet Rheumatol
. 2024 Feb;
6(4):e226-e236.
PMID: 38402891
Background: Antidrug antibodies to TNF inhibitors might affect clinical outcomes. Proactive therapeutic drug monitoring allows for early detection of antidrug antibodies and might reduce negative clinical consequences. We aimed to...
5.
Brun M, Bjorlykke K, Viken M, Stenvik G, Klaasen R, Gehin J, et al.
J Intern Med
. 2023 Feb;
293(5):648-655.
PMID: 36843323
Background: Immunogenicity to tumour necrosis factor inhibitors is a significant clinical problem leading to treatment failure and adverse events. The study aimed to assess human leukocyte antigen (HLA) associations with...
6.
Brun M, Goll G, Jorgensen K, Sexton J, Gehin J, Sandanger O, et al.
J Intern Med
. 2022 Apr;
292(3):477-491.
PMID: 35411981
Background: Anti-drug antibodies (ADAb) frequently form early in the treatment course of infliximab and other tumour necrosis factor (TNF) inhibitors, leading to treatment failure and adverse events. Objective: To identify...
7.
Syversen S, Jorgensen K, Goll G, Brun M, Sandanger O, Bjorlykke K, et al.
JAMA
. 2021 Dec;
326(23):2375-2384.
PMID: 34932077
Importance: Proactive therapeutic drug monitoring (TDM), consisting of individualized treatment based on scheduled assessments of serum drug levels, has been proposed as an alternative to standard therapy to optimize efficacy...
8.
Syversen S, Goll G, Jorgensen K, Sandanger O, Sexton J, Olsen I, et al.
JAMA
. 2021 May;
325(17):1744-1754.
PMID: 33944876
Importance: Proactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on scheduled monitoring of serum drug levels, has been proposed as an alternative to standard therapy to maximize...
9.
Syversen S, Goll G, Jorgensen K, Olsen I, Sandanger O, Gehin J, et al.
Trials
. 2020 Jan;
21(1):13.
PMID: 31907007
Background: Infliximab (INX) and other tumour necrosis factor inhibitors (TNFi) have revolutionised the treatment of several immune mediated inflammatory diseases. Still, many patients do not respond sufficiently to therapy or...
10.
Ingvaldsen C, Leegaard T, Kravdal G, Mork C
Acta Derm Venereol
. 2019 Oct;
100(1):adv00005.
PMID: 31612235
Infectious pseudochromhidrosis is a rare dermatological disorder, characterized by a change in colour of the sweat from normal skin, caused by pigments from microorganisms. Such pigments are a result of...